The study built on existing data that showed diabetes was one of the comorbidities for which people were at a higher risk for severe COVID-19 infection, likely resulting in hospitalization at least. However, this latest research from the Hebrew University of Jerusalem, the Meuhedet HMO, Jerusalem College of Technology (JCT), and Hadassah Medical Center represented the first study to explore the correlation between sugar levels and the risk of severe COVID-19 morbidity regardless of diabetes diagnosis.
While the highest risk of existing patients diagnosed with diabetes of contracting severe COVID-19 (1 of 4) was found in patients with low sugar values — below 80 mg/dl, the lowest risk (1 of 12) was found in patients with sugar values of 106-125 mg/dl. (The standard blood sugar level for an adult is 70-100 mg/dL, after having fasted at least eight hours).
Patients with sugar values while fasting of 105-125 mg/dl were one-and-a-half times more at risk of developing severe COVID-19 than patients with sugar values less than 105. Patients with sugar values of 125-140 mg/dl were twice as likely to develop COVID-19 complications than patients with sugar values less than 105.
The study examined all members of the Mehudet HMO, who are over the age of 18, including some 37,000 subjects (16.7 percent of the total group) who registered a positive COVID-19 PCR test between March and October 2020.
“The aim of the study was to locate risk factors for COVID-19 severe morbidity which could be handled in advance, so we could raise the awareness of those factors among the general public,” said Dr. Michal Shauly-Aharonov of the Department of Industrial and Management Engineering at JCT and Hebrew University’s School of Public Health in a statement from the Jerusalem College of Technology (JCT).
“Locating factors related to severe morbidity and death, G-d forbid, is important principally to shed light on the populations at risk, so they can receive priority in receiving vaccines. As far as we know, no population-based studies had previously been published correlating glucose levels before infection and the risk level of contracting COVID-19 in patients suffering or not suffering from diabetes.”
Dr. Orit Bernholtz-Gulchin, head of the Meuhedet HMO regional diabetes clinic, said the findings meant that the medical community’s emphasis “should be placed on preventing hypoglycemia (a condition in which blood sugar level drops radically from normative levels) in populations found to be at risk of severe COVID-19 comorbidity.”
Research has shown that COVID-19 patients with diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular diseases (CVD), hypertension, and other comorbidities — as well as old age — could help it develop into a more serious-life-threatening illness. Doctors and medical professionals have been aware of this since early into the pandemic.
The researchers also recommended paying special attention to patients with no diagnosis of diabetes who show abnormal sugar levels during fasting or who show elevated HbA1C hemoglobin levels, as well as low sugar-value diabetics, who are also at increased risk of COVID-19 complications.
“The study shows very strongly how much can be learned from quality and continuous medical recording, such as the one we have in the Israeli health care system,” said Prof. Ora Paltiel of Hebrew University’s School of Public Health.
Meanwhile, Israeli data from the COVID-19 booster shot program, which the government rolled out on August 1, and has administered inoculation shots to nearly three million people so far, will be used to guide vaccine advisers to the US Food and Drug Administration (FDA).
The data will be peer-reviewed in the New England Journal of Medicine, a key step in helping the FDA’s Vaccines and Related Biological Products Advisory Committee when they meet on September 17. Their findings will be instrumental in whether the United States rolls out its own booster vaccination program.
A recent study from UAE reported 10% mortality among COVID-19 patients with diabetes . For newly diagnosed diabetic cases, mortality and mechanical ventilation needs were considerably higher relative to people with pre-existing diabetes. Patients with COVID-19 infection are negatively impacted by uncontrolled hyperglycemia.
A potential risk of complications is recently diagnosed and previously undiagnosed hyperglycemia .
Glycemia adjustment in hospitalized patients is vital in the context of the COVID-19 pandemic, and screening to identify undiagnosed cases of diabetes is markedly important . A meta-analysis reported a 9.7% prevalence of diabetes mellitus (DM) in COVID-19 patients in China , which is comparable to the DM prevalence in China.
A UK study described hospital death of 23,804 COVID-19 patients, of which 32% had type 2 DM and 1.5% had type 1 DM, with 2.03- and 3.5-fold risk of death in hospital relative to non-DM patients, respectively . A retrospective Chinese study suggested that COVID-19 patients with diabetes had a higher incidence of hypertension (56.9%), cardiovascular disease (CVD) (20.9%), and cerebrovascular disease (7.8%) compared to non-DM patients (28.8, 11.1, and 1.3%, respectively) .
A population-based cohort study from England reported a greater possibility of death from COVID-19 in patients with diabetes (either type 1 or type 2 DM) with HbA 1c > 10% relative to those with HbA 1c < 6.5% .
How COVID-19 impacts DM patients
DM is a metabolic disease illustrated by chronic high circulating blood glucose concentration in the body . The worldwide prevalence of DM has increased drastically, with 463 million people suffering from the disease globally in 2019, with 95% of type 2 DM . Currently, many patients who have diabetes remain undiagnosed with the disease. The therapeutic intervention has reduced disease complications, making it necessary to detect diabetes early on in its course.
DM occurs throughout the world, but it is found explicitly in the more developed countries, where the majority of the patients are in the age group between 45 and 64 years. A relationship has been clinically recognized between diabetic individuals and infections . A virus that causes pneumonia, particularly influenza, is prevalent and presents a much more profound threat in older patients with type 2 DM [23,24].
There is a higher chance of poor prognosis and death for COVID-19 patients with diabetes. With the high global incidence of diabetes, these individuals constitute a significant portion of the population susceptible to COVID-19. Several factors are linked with a higher risk of mortality from COVID-19, including male gender, increased age, hypertension, DM, obesity, CVDs, chronic obstructive pulmonary disease, and cancer .
Reports from countries such as China [13,17,19], Italy , and the City of New York  have shown that older age and chronic diseases such as DM, hypertension, and extreme obesity are now considered to augment morbidity and death in COVID-19 patients. It is indistinct whether DM leads individually to elevated risk, but blood glucose and DM predict morbidity and death in SARS patients .
An American study reported that in 1,122 patients admitted in hospital for COVID-19, the rate of mortality during hospital stays of those suffering from diabetes or hyperglycemia was four-fold higher (28.8%) than that of patients with normal glucose level (6.2%) .
A reduced chance of complications and the all-cause death rate were also linked with good glycemic regulation . Al Hayek et al. investigated the factors that may raise the risk of hospital admission of COVID-19 patients with diabetes. They reported patients’ hospitalization was independently associated with a high HbA1c level in Saudi patients .
A Chinese meta-analysis reported that high HbA1c is a predictor of the in-hospital mortality of COVID-19 patients . Individuals with elevated HbA1c are at high risk for COVID-19. They should comply with the doctor’s recommendation and precisely track and regulate glucose metabolism regularly . It has been proposed that diabetes could potentiate the severity of SARS-CoV-2 infection via diverse routes that eventually contribute to advanced glycation end products, glucose toxicity, endotheliitis, vital organ injury, and fatality .
It is reported that ACE2 receptors mediate the SARS-CoV-2 effects in the host cells. ACE2 receptors are present in the respiratory system, type 1 and 2 alveolar cells of the lungs, hearts, kidney tubules, enterocytes, and pancreas. Studies conducted on rodent models of DM have demonstrated that there has been an augmented manifestation of ACE2 receptors in the lungs, heart, kidney, and pancreas [33,34].
Furthermore, a randomized study found that increased lung ACE2 expression was linked with DM . Furthermore, DM patients have higher circulating Furin levels, a cellular protease that cleaves S1 and S2 domains of spike protein, facilitating the access of SARS-CoV-2 .
These studies support that DM patients present a higher COVID-19 risk, and diabetic individuals infected with the disease have impaired virus clearance . ACE2 helps in the catalytic conversion of angiotensin 2 to angiotensin 1–7 or angiotensin 1–9. This conversion is essential as it has a protective effect on the lungs against ARDS . This protective action is because of the antioxidant and anti-inflammatory action of angiotensin 1–7 and angiotensin 1–9. Unfortunately, once the SARS-CoV-2 virus binds with ACE2, it is degraded, preventing any protective action toward the lung parenchyma. This allows angiotensin 2 to cause lung injury .
Furthermore, there is more potassium loss in the urine and increased aldosterone secretion by the virus . Nevertheless, more studies need to be conducted to assess the full potential effects of ACE2 expression concerning diabetes and COVID-19. Predictions and decisions can be made if angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, TZDs, GLP-1 agonists, and statins reduce ACE2 appearance in COVID patients.
DM also causes impairment in the activation of the adaptive immune response by inhibiting stimulation of Th1 cell-mediated immunity, thereby leading to a delayed hyperinflammatory reaction in diabetic patients . A study that examined DM effects in mouse models of MERS-Cov infectivity showed that the infection was further prolonged and severe in diabetic male mice. This was because of the variations in CD4+ T cell counts and aberrant cytokine responses .
This finding is fairly consistent with SARS-CoV-2 patients, with peripheral counts of CD4+ and CD8T cell counts being abnormally low but subsequently having higher levels of proinflammatory Th17 cells and elevated cytokine count [42,43]. This demonstrated that DM patients have a severely blunted anti-viral response compared to a fairly accentuated inflammatory response because of delayed activation of Th1/Th17 . The SARS-CoV-2 productively infects β-cell and can trigger acute insulin secretion impairment or β-cells loss, which can initiate diabetes .
To understand the possible causal association between chronic untreated hyperglycemia and higher death rates in COVID-19 patients, certain biological pathways have been suggested. The primary cause of mortality in COVID-19 patients with diabetes is an inadequate immune response to viral infections .
The increased blood sugar level is expected to substantially affect the intracellular degradation of bacteria, neutrophil chemotaxis, and phagocytosis, thus improving viral binding affinity and entry and decreasing virus clearance . In addition, it has significant effects on the proteins by inducing glycosylation and altering the composition of complements [47,48], and glycosylation renders cells susceptible to viral inflammation and damage [49,50].
In addition, endotheliitis may be a potential pathway that triggers organ dysfunction that causes essential COVID-19 disease, aggravated by endothelial dysfunction coupled with chronic hyperglycemia .
Multiple variables are associating diabetes with infection severity. The acute inflammatory response can be triggered, intensified, or prolonged by hyperglycemia . It also induces a coagulation and fibrinolysis mismatch, resulting in elevated coagulation factors and relative fibrinolytic system inhibition, fostering a pro-coagulant state . Moreover, SARS-CoV-2 is suspected to be using the ACE2 as the entry receptors on the Langerhans islets. This can lead to moderate to dawning of these cells, leading to moderate hyperglycemia to life-endangering diabetic ketoacidosis .
Diabetic people’s vulnerability during a public health epidemic turns out to be evident in the COVID-19 pandemic because of their at least twice higher risk of severe illness or death, particularly in people with poorly regulated diabetes and comorbidities, or both. The pressure on healthcare organizations and the world economy because of COVID-19, compounded by chronic diseases like diabetes, has been enormous  (Table 1).
An extensive survey showed that respondents had a low knowledge score regarding COVID-19. In this respect, it becomes more important to be aware of COVID-19 and its consequences on human health . Establishing a valid association between DM and COVID-19 is imperative in treating DM patients.
It would also help in DM care in the present conditions and assist in similar outbreaks in the future. It is also essential to take care of the comorbidities of DM patients while treating DM. Now that the COVID-19 vaccine is available, we need to get vaccinated to save ourselves from this highly infectious disease and save other society members.
The community must also implement social distancing guidelines and protocols to protect those who are more susceptible to morbidity from this disease, such as comorbid individuals or older aged people. Comorbid individuals are those who are more severely being infected by the virus. Patients with chronic illnesses like diabetes, hypertension, and respiratory diseases are more threatened by the virus than those without any underlying conditions.
The treatment of COVID-19 patients with diabetes requires an integrated team approach to minimize the risk of medical complications and mortality . Besides, doctors should incorporate pragmatic measures to treat patients with comorbidities. This strategy would help reduce the frequency of complications, mortality among patients, and the healthcare system’s overall load.
reference link : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010370/